April 16, 2026 – Healventures

Funding the “Million‑Dollar Miracle”

Medicine is shifting from lifelong disease management to one‑time cures. Yet we’re still trying to fund 21st‑century breakthroughs with 20th‑century payment systems. As cell and

April 16, 2026 No Comments

The Future of Asian Biotech: Bridging the "Valley of Death" | AHA Q1 2026 Recap

What is the state of healthcare investment in 2026? In this special session of the Alliance of Healthcare Investors in Asia (AHA), we convene a closed-door panel of investors, operators, ...and strategics from Singapore, China, Korea, Taiwan, and the US.

The consensus is clear: Biotech is cross-border by default. We break down the shift toward early-stage innovation and how Asia is uniquely positioned to capture value where global capital has traditionally pulled back.

Key Discussion Points:
- Asset Selection: Why "strong science" is only the beginning—how to identify assets that compound in value.
- The "Valley of Death": Capitalizing on the gap in early-stage development while global markets focus on de-risked assets.
- The China-Singapore Pathway: A strategic look at originating IP in China and leveraging Singapore for global translational development.
- Navigating Cross-Border Complexity: Why regulatory and commercial success now requires a multi-geography strategy.

00:00 Introduction: The Future of Asian Biotech
35:31 Keynote: The BlueJay Therapeutics Story (Dr. Keting Chu)
1:11:21 The Funding Shift: Navigating the "Valley of Death"
1:29:46 The Scientist’s Edge: Why Science is the Only Metric
1:40:24 Strategic Corridor: Bridging China and Singapore
2:02:47 Global Regulatory Strategy: Speed vs. Market Size
2:23:13 Regional Market Access: Mutual Recognition & Work Sharing ClosingShow More

Day: April 16, 2026

Funding the “Million‑Dollar Miracle”

The Future of Asian Biotech: Bridging the "Valley of Death" | AHA Q1 2026 Recap